This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.3 kDa. The protein migrates as 60-75 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human PD-L1, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human PD-L1, Fc Tag (Cat. No. PD1-H5258) was more than 90% and the molecular weight of this protein is around 115-150 kDa verified by SEC-MALS.
Immobilized Human PD-L1, Fc Tag (Cat. No. PD1-H5258) at 5 μg/mL (100 μL/well) can bind Anti-PD-L1 MAb with a linear range of 0.2-2 ng/mL (Routinely tested).
Loaded Human PD-1, His Tag (Cat. No. PD1-H5221) on HIS1K Biosensor, can bind Human PD-L1, Fc Tag (Cat. No. PD1-H5258) with an affinity constant of 38.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human PD-L1, Fc Tag (Cat. No. PD1-H5258) on Protein A Biosensor, can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 18 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human PD-L1, Fc Tag (Cat. No. PD1-H5258) on Protein A Biosensor, can bind Human Human PD-1, His Tag, low endotoxin (Cat. No. PD1-H522a) with an affinity constant of 4.8 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human PD-L1, Fc Tag (Cat. No. PD1-H5258) on Protein A Biosensor, can bind Human Human PD-1, Strep Tag (Cat. No. PD1-H5284) with an affinity constant of 2.5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Flow Cytometry assay shows that Human PD-L1, Fc Tag (Cat. No. PD1-H5258) can bind to 293 cell overexpressing human PD-1. The concentration of PD-L1 used is 10 μg/mL (Routinely tested).
FACS analysis shows that the binding of Human PD-L1, Fc Tag (HPLC-verified) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing Anti-PD-L1 antibody. The concentration of PD-L1 used is 10 μg/mL. The IC50 is 12.92 μg/mL (Routinely tested).
Immobilized cell surface PD-1 (5x104 of cells per well) can bind Human PD-L1, Fc Tag (Cat. No. PD1-H5258) with an EC50 of 0.029 μg/mL (Routinely tested).
Authors: X Qian, et al
Journal: US20190330348A1 2019
Application: immunization & ELISA
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Authors: Ganesan A, et al
Journal: Sci Rep 2019
Application: SPR
Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction
Authors: Boohaker RJ, et al.
Journal: Cancer Lett 2018
Application: BLI
Authors: Yam Alice, et al.
Journal: US20180142022A1 2018
Application: ELISA
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $319.00
Price(USD) : $2310.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.
A-Z
